Fearon et al., 2018 - Google Patents
PHLDA1 mediates drug resistance in receptor tyrosine kinase-driven cancerFearon et al., 2018
View HTML- Document ID
- 14670358647102284004
- Author
- Fearon A
- Carter E
- Clayton N
- Wilkes E
- Baker A
- Kapitonova E
- Bakhouche B
- Tanner Y
- Wang J
- Gadaleta E
- Chelala C
- Moore K
- Marshall J
- Chupin J
- Schmid P
- Jones J
- Lockley M
- Cutillas P
- Grose R
- Publication year
- Publication venue
- Cell reports
External Links
Snippet
Development of resistance causes failure of drugs targeting receptor tyrosine kinase (RTK) networks and represents a critical challenge for precision medicine. Here, we show that PHLDA1 downregulation is critical to acquisition and maintenance of drug resistance in RTK …
- 101710031170 PHLDA1 0 title abstract description 127
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fearon et al. | PHLDA1 mediates drug resistance in receptor tyrosine kinase-driven cancer | |
Liu et al. | Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma | |
Chen et al. | Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13 | |
Takaku et al. | GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network | |
Wang et al. | Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer | |
Elkabets et al. | AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas | |
Corre et al. | Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma | |
Zhao et al. | Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer | |
Zhang et al. | TRAF4 promotes TGF-β receptor signaling and drives breast cancer metastasis | |
Mendoza‐Naranjo et al. | ERBB 4 confers metastatic capacity in ewing sarcoma | |
Arienti et al. | Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer | |
Jbara et al. | RBFOX2 modulates a metastatic signature of alternative splicing in pancreatic cancer | |
Lee et al. | Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer | |
Kiso et al. | Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network | |
Zhang et al. | FOXK2 suppresses the malignant phenotype and induces apoptosis through inhibition of EGFR in clear‐cell renal cell carcinoma | |
Chen et al. | Characterization of tumor suppressive function of cornulin in esophageal squamous cell carcinoma | |
Wu et al. | A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop | |
Du et al. | CircNFIB inhibits tumor growth and metastasis through suppressing MEK1/ERK signaling in intrahepatic cholangiocarcinoma | |
Xu et al. | circEYA1 functions as a sponge of miR-582-3p to suppress cervical adenocarcinoma tumorigenesis via upregulating CXCL14 | |
Rose et al. | OASIS/CREB3L1 is epigenetically silenced in human bladder cancer facilitating tumor cell spreading and migration in vitro | |
Jin et al. | Cooperative interaction between the MUC1-C oncoprotein and the Rab31 GTPase in estrogen receptor-positive breast cancer cells | |
Cheng et al. | Overexpression of wild-type but not C134W mutant FOXL2 enhances GnRH-induced cell apoptosis by increasing GnRH receptor expression in human granulosa cell tumors | |
Dufour et al. | TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer | |
Mus et al. | The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness | |
Antas et al. | SH3BP4 regulates intestinal stem cells and tumorigenesis by modulating β-catenin nuclear localization |